Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
Abstract Biologics are increasingly being co‐developed in combination or as novel constructs like bispecific antibodies (BsAbs) with the goal of targeting multiple, non‐redundant mechanisms of action. Rational design of combinations and dual‐targeting approaches that consider disease complexities ha...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley
2022-09-01
|
| סדרה: | Clinical and Translational Science |
| גישה מקוונת: | https://doi.org/10.1111/cts.13345 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|